Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 6, 2005

 

 

INVITROGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Delaware   0-25317   33-0373077

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

1600 Faraday Avenue, Carlsbad, CA   92008
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (760) 603-7200

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Section 8 – Other Events

 

Item 8.01 Other Events.

 

Dr. Jay M. Short, the Chairman and Chief Executive Officer of Diversa Corporation, and a director of three additional publicly traded companies, including Invitrogen Corporation, has committed to retire from the Board of Directors of one of the publicly traded companies (other than Invitrogen) within the next six months. He announced his intent to serve on the board of directors of no more than three publicly traded companies so long as he remains the Chief Executive Officer of Diversa Corporation.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Invitrogen Corporation
    (Registrant)
Date April 6, 2005  

/s/ David F. Hoffmeister

    David F. Hoffmeister
    Sr. Vice President, Chief Financial Officer